Literature DB >> 29613858

The Medical Necessity of Comprehensive Patch Testing.

Tian Hao Zhu, Raagini Suresh1, Erin Warshaw, Pamela Scheinman2, Christen Mowad3, Nina Botto4, Bruce Brod5, James S Taylor6, Amber Reck Atwater7, Kalman Watsky8, Peter C Schalock9, Brian C Machler10, Stephen Helms11, Sharon E Jacob12, Jenny E Murase.   

Abstract

Allergic contact dermatitis is associated with significant disease and economic burden in the United States. To properly manage allergic contact dermatitis, it is important to accurately identify the substance(s) implicated in the dermatitis to prevent disease recurrence. The commercially available T.R.U.E Test (36 allergens) screening panel has been reported to have a conservative hypothetical allergen detection rate of 66.0%, at most. Importantly, these calculations are based on the 78% of patients who had clinically relevant reactions to allergens present on the North American Contact Dermatitis Group screening series (70 allergens), without the use of supplemental allergens. Testing with supplemental allergens beyond a screening series can more fully evaluate an individual's environmental and occupational exposure, which may significantly increase diagnostic accuracy. Comprehensive patch testing with additional allergens in sunscreens, cosmetics, and fragrances, for example, may increase the diagnostic yield as well as the likelihood of achieving a cure if the dermatitis is chronic and recalcitrant.

Entities:  

Mesh:

Year:  2018        PMID: 29613858     DOI: 10.1097/DER.0000000000000362

Source DB:  PubMed          Journal:  Dermatitis        ISSN: 1710-3568            Impact factor:   4.845


  3 in total

1.  Prevalence of Contact Allergens in Natural Skin Care Products From US Commercial Retailers.

Authors:  Peter A Young; Haiwen Gui; Gordon H Bae
Journal:  JAMA Dermatol       Date:  2022-09-14       Impact factor: 11.816

2.  Seven Common Allergen Groups Causing Eyelid Dermatitis: Education and Avoidance Strategies.

Authors:  Crystal X Huang; James A Yiannias; Jill M Killian; Joanne F Shen
Journal:  Clin Ophthalmol       Date:  2021-04-12

3.  The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy.

Authors:  Raagini Suresh; Jenny E Murase
Journal:  JAAD Case Rep       Date:  2018-10-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.